In landmark single-cell study of pancreatic tumors, UC San Diego Moores Cancer Center researchers reveal how tumor evolution shapes disease, which could yield new, more effective treatments for one of the deadliest cancers.

Over decades of sustained, integrated national viral hepatitis control, Japan has seen substantial reductions in HBV- and HCV-related disease burden and hepatocellular carcinoma mortality.

More than 4 out of 5 families experiencing treatment for childhood leukemia were impacted by employment or marital status changes during care according to new research in JNCCN.

Genetic alterations in TP53 and CDKN2A can shape the immune response during early oral cancer development. Researchers from Tokushima University reveal that imbalanced p53–RB signaling activated the cGAS–STING pathway, allowing increased inflammatory signaling and infiltration of cytotoxic T cells and natural killer cells. This immune response was associated with delayed progression to invasive oral cancer. The findings highlight how specific tumor-suppressor alterations can influence antitumor immunity and progression during early carcinogenesis.

A small number of random genetic mutations cause simple RNA droplets to transform into cell-like structures. In this process, they form cavities, can move and are able to take up cargo. This has been demonstrated through research using nanostructures based on ribonucleic acid led by Prof. Dr. Kerstin Göpfrich at the Center for Molecular Biology of Heidelberg University (ZMBH) in cooperation with experts from the German Cancer Research Center and the University of Augsburg. Just a few molecular changes are enough to trigger these complex processes in very simple synthetic cells – a principle that the researchers also hope to harness for medical applications.

Researchers at The University of Texas MD Anderson Cancer Center and collaborating institutions in Texas developed an artificial intelligence (AI) model that helps explain how immune cells find their way to specific locations in the body and why they avoid others. The findings could help scientists better understand cancer, autoimmune diseases and treatment response.

Scientists have developed a simple yet powerful strategy to overcome a long-standing challenge in cancer phototheranostics—the trade-off between imaging brightness, therapeutic efficacy, and biological stability. By systematically replacing hydrogen atoms with deuterium (a heavier isotope) in a near-infrared fluorescent molecule, researchers achieved simultaneous improvements in all three critical properties. The optimized nanoparticles delivered 26% higher fluorescence brightness, 14% more reactive oxygen species for killing cancer cells, and 20% better stability in blood. In mouse models, a single treatment completely eliminated breast tumors, and fluorescence-guided surgery enabled precise removal of colorectal cancer remnants that were invisible under white light—extending survival from under 20 days to over 60 days. The strategy is broadly applicable and does not require redesigning the molecular backbone, offering a versatile platform for next-generation cancer theranostics.